Three-year follow-up from a phase 3 study of SB3 (a trastuzumab biosimilar) versus reference trastuzumab in the neoadjuvant setting for human epidermal growth factor receptor 2–positive breast cancer

  1. Pivot, X.
  2. Pegram, M.
  3. Cortes, J.
  4. Lüftner, D.
  5. Lyman, G.H.
  6. Curigliano, G.
  7. Bondarenko, I.
  8. Yoon, Y.C.
  9. Kim, Y.
  10. Kim, C.
Aldizkaria:
European Journal of Cancer

ISSN: 1879-0852,  0959-8049

Argitalpen urtea: 2019

Alea: 120

Orrialdeak: 1-9

Mota: Artikulua

DOI: 10.1016/J.EJCA.2019.07.015 GOOGLE SCHOLAR lock_openSarbide irekia editor
Datuen iturria: Scopus